Ross Everett, MD
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,000 of the $18,288 with a category attached, or 65.6%. Intuitive Surgical accounts for 71.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $13,048 and has fallen 90.1% since, to $1,295 in 2025.
Across 77 payments — averaging $237.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- Coloplast$3K
- Procept Biorobotics Corporation$612
- Endo USA, Inc.$463
- Boston Scientific$462
- Innovation Technologies Inc$169
- plus $145 from 1 others
What the payments were for
- Speaking & faculty fees$1,0005%
- Travel & lodging$9055%
- Food & beverage$4,38324%
- Education$12,00066%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $13,000 |
| Coloplast | 49 | $3,438 |
| Procept Biorobotics Corporation | 6 | $612 |
| Endo USA, Inc. | 4 | $463 |
| Boston Scientific | 11 | $462 |
| Innovation Technologies Inc | 1 | $169 |
| Baxter Healthcare | 1 | $145 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$9,000
- DAVINCI XI$3,000
- TITAN$1,110
- VIRTUE$1,003
- Da Vinci Surgical System$1,000
- XIAFLEX$401
- ALTIS$373
- AquaBeam Robotic System$284
- Irrisept$169
- TISSEEL$145
- SpaceOAR VUE System - 10mL$139
- AQUABEAM SYSTEM$125
- AVEED$122
How this compares
$18,288 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 22 | $23,196 |
| MyrbetriqMirabegron | 14 | $13,113 |
| Tamsulosin Hcl | 94 | $954 |
| Testosterone Cypionate | 16 | $677 |
| Finasteride | 29 | $308 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $222 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $62 |
Paid to pharmacies, not to this prescriber.
Other urology in Tampa
- Rafael CarrionTampa$240K
- Raviender BukkapatnamTampa$115K
- Trushar PatelTampa$88K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.